The UF Health Proton Therapy Institute enhanced its playroom, a respite for its pediatric patients, significantly with innovative technology that promotes therapeutic engagement, with an 86” interactive gaming wall that features educational and sensory software.
FDA approved cabozantinib (Cabometyx) for adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors and well-differentiated extra-pancreatic neuroendocrine tumors.
